Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 2,182 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 2,182 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $204.10, for a total transaction of $445,346.20. Following the completion of the sale, the insider owned 145,700 shares in the company, valued at approximately $29,737,370. This trade represents a 1.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, April 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $202.30, for a total transaction of $606,900.00.
• On Tuesday, March 10th, Solomon Moshkevich sold 915 shares of Natera stock. The stock was sold at an average price of $204.13, for a total transaction of $186,778.95.
• On Monday, March 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $199.85, for a total transaction of $599,550.00.
• On Tuesday, February 3rd, Solomon Moshkevich sold 1,639 shares of Natera stock. The shares were sold at an average price of $230.77, for a total transaction of $378,232.03.
• On Monday, February 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $231.44, for a total transaction of $694,320.00.

Natera Trading Down 2.7%

Shares of NASDAQ:NTRA opened at $194.75 on Thursday. The company has a market capitalization of $27.71 billion, a price-to-earnings ratio of -127.29 and a beta of 1.68. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $256.36. The firm’s 50-day moving average is $202.22 and its 200 day moving average is $213.80.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, beating the consensus estimate of ($0.46) by $0.81. The company had revenue of $665.50 million for the quarter, compared to the consensus estimate of $600.68 million. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. During the same period in the prior year, the firm posted ($0.41) EPS. As a group, equities analysts forecast that Natera, Inc. will post -1.71 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on NTRA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a report on Tuesday, April 21st. Wall Street Zen upgraded shares of Natera from a “hold” rating to a “buy” rating in a report on Saturday, April 18th. Robert W. Baird upped their price target on shares of Natera from $239.00 to $257.00 and gave the company an “outperform” rating in a report on Friday, February 27th. Canaccord Genuity Group reiterated a “buy” rating on shares of Natera in a report on Monday, January 12th. Finally, Wells Fargo & Company upped their price target on shares of Natera from $205.00 to $215.00 and gave the company an “equal weight” rating in a report on Friday, February 27th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $253.47.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Recent operating results and analyst interest provide a bullish backdrop: Natera reported an upside quarter (Feb. 26) with revenue and EPS above consensus, and multiple firms maintain buy/overweight views and price targets above the current price — a structural tailwind if execution continues.
• Positive Sentiment: Large institutional buying in recent quarters (e.g., Coatue, Wellington added sizable positions) indicates continued conviction from some allocators, which can limit downside and support recovery after volatility. Quiver Quant: Natera shares slide
• Neutral Sentiment: Multiple insider sales have been announced (CEO, CFO and other executives) but were executed under pre‑arranged Rule 10b5‑1 plans and primarily to cover tax withholdings on vested awards — routine from a governance perspective but can be interpreted differently by the market. See one SEC disclosure for the CFO sale on Apr. 29. CFO Form 4 (Apr 29)
• Negative Sentiment: Near-term de‑risking ahead of the May 7 earnings print has pressured the stock — several market summaries point to position‑sizing into the report, which increases short‑term volatility and drove selling momentum. Quiver Quant: Natera shares slide
• Negative Sentiment: Analyst caution and supply/overhang concerns: a recent downgrade to hold (circulated in April) and a string of Form 144/insider sale disclosures have kept investors focused on potential selling pressure; investors may also be scrutinizing management’s 2026 revenue/gross‑margin guidance as a tougher setup after strong prior growth. Yahoo Finance: Should You Be Bullish on Natera?

Institutional Investors Weigh In On Natera

Several large investors have recently added to or reduced their stakes in NTRA. Coatue Management LLC boosted its position in Natera by 1,446.1% in the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after buying an additional 2,463,008 shares during the period. Wellington Management Group LLP boosted its position in Natera by 94.7% in the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after buying an additional 2,420,263 shares during the period. Norges Bank purchased a new stake in Natera in the 4th quarter valued at about $372,398,000. JPMorgan Chase & Co. boosted its position in Natera by 10.5% in the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after buying an additional 1,225,420 shares during the period. Finally, Franklin Resources Inc. boosted its position in Natera by 37.5% in the 3rd quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock valued at $428,987,000 after buying an additional 727,366 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.